Effects of 5-bromotetrandrine and daunorubicin on apoptosis and expression of survivin in K562/A02 cells]

Xiao-Hui Cai,Bao-An Chen,Jian Cheng,Jun Wang,Jia-Hua Ding,Wen Bao,Yue-Jiao Zhong,Feng Gao,Wen-Lin Xu,Hui-Ling Shen,Hu-Lai Wei,Jing Chen
2011-01-01
Abstract:The aim of this study was to investigate the potential benefit of combination therapy with 5-bromotetrandrine (5-BrTet) and daunorubicin (DNR) on chronic leukemia. The apoptosis of K562/A02 cells treated by DNA, BrTet and BrTet combined with DNR for 48 hours was detected by flow cytometry; the expressions levels of survivin mRNA and protein K562/A02 cells treated by DNR, BrTet and BrTet combined with DNR and in untreated K562 cells for 48 hours were measured by RT-PCR and Western blot respectively. The results showed that the combination of BrTet with DNR increased apoptotic rate of K562/A02, down-regulated the expression levels of survivin mRNA and protein in K562/A02 cells as compared with blank control and cells treated by BrTet or DNR alone, the survivin expression in K562/A02 cells was higher than that in K562 cells. It is concluded that the combination of BrTet with DNR can effectively reverse the multidrug resistance of K562/A02 cells, promote the apoptosis of K562/A02 cells, the mechanism of which may be related with down-regulation of survivin expression. Survivin may be a target for the treatment of MDR in hematopoietic malignancies.
What problem does this paper attempt to address?